MabThera licence extended

The monoclonal antibody MabThera (rituximab) can now be prescribed for the maintenance treatment of follicular lymphoma in patients who have responded to induction therapy.

The licence extension was granted following the results of the PRIMA trial, in which patients who received rituximab alone as maintenance therapy every 2 months for 2 years following induction therapy with rituximab and chemotherapy had their risk of relapse halved compared with those who stopped treatment with rituximab after induction therapy.

View MabThera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more